var data={"title":"Arsenic trioxide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Arsenic trioxide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5668?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">see &quot;Arsenic trioxide: Drug information&quot;</a> and <a href=\"topic.htm?path=arsenic-trioxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Arsenic trioxide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708626\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Differentiation syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain or peripheral edema, hypotension, and renal, hepatic, or multiorgan dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. Temporary discontinuation of arsenic trioxide may be required.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">QT prolongation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block, and a torsade des pointes-type ventricular arrhythmia, which can be fatal. Before initiating therapy, assess the QTc interval, correct preexisting electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with ventricular arrhythmia or prolonged QTcF.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136731\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Trisenox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781459\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Trisenox </li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999071\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999096\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">see &quot;Arsenic trioxide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute promyelocytic leukemia (APL), initial treatment:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Single-agent </i>(Mathews 2006): Children and Adolescents: Dosing based on experience available for children &ge;3 years; however, age was not an exclusion criteria in clinical trial</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: IV: 0.15 mg/kg/day (maximum dose: 10 mg/dose); administer daily until bone marrow remission; maximum induction: 60 doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation: IV: 0.15 mg/kg/day (maximum dose: 10 mg/dose) for 4 weeks, starting 4 weeks after completion of induction therapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: IV: 0.15 mg/kg/dose (maximum dose: 10 mg/dose) administered 10 days per month for 6 months, starting 4 weeks after completion of consolidation therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>In combination with tretinoin and gemtuzumab in high-risk APL</i> (Ravandi 2009): Children and Adolescents: Dosing based on experience available for adolescents &ge;14 years; however, age was not an exclusion criteria in clinical trial</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction (beginning 10 days after initiation of tretinoin): IV: 0.15 mg/kg/day until bone marrow remission; maximum induction: 75 doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation: IV: 0.15 mg/kg/day Monday through Friday for 4 weeks every 8 weeks for 4 cycles (weeks 1 to 4, 9 to 12, 17 to 20, and 25 to 28)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>In combination with tretinoin, idarubicin, and prednisone (APML4 protocol)</i> (Iland 2012): Children &gt;1 year and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: IV: 0.15 mg/kg/day over 2 hours on days 9 to 36 (in combination with tretinoin and idarubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation: IV: 0.15 mg/kg/day on days 1 to 28 of consolidation cycle 1 (in combination with tretinoin); 0.15 mg/kg/day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, and 29 to 33 of consolidation cycle 2 (in combination with tretinoin); 2 cycles total</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute promyelocytic leukemia (APL), relapsed or refractory:</b> Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: IV: 0.15 mg/kg/day; administer daily until bone marrow remission; maximum induction: 60 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Consolidation: IV: 0.15 mg/kg/day starting 3 to 6 weeks after completion of induction therapy; maximum consolidation: 25 doses over a period of up to 5 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Note:</b> Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute promyelocytic leukemia (APL), relapsed or refractory</b>: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 0.15 mg/kg/day; administer daily until bone marrow remission; maximum induction: 60 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Consolidation: 0.15 mg/kg/day starting 3 to 6 weeks after completion of induction therapy; maximum consolidation: 25 doses over a period of up to 5 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (CrCl &ge;30 mL/minute): There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe renal impairment (CrCl &lt;30 mL/minute): Use with caution (systemic exposure to metabolites may be higher); may require dosage reduction; monitor closely for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Patients with severe impairment (Child-Pugh class C) should be monitored closely for toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136716\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trisenox: 10 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trisenox: 12 mg/6 mL (6 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136702\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999102\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Do not mix with other medications. Infuse over 1 to 2 hours. If acute vasomotor reactions occur, may infuse over a maximum of 4 hours. Does not require administration via a central venous catheter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130882\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136727\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials/ampules at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Following dilution in D5W or NS, solutions diluted for infusion are stable for 24 hours at room temperature or 48 hours when refrigerated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999072\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Remission induction and consolidation in patients with relapsed or refractory acute promyelocytic leukemia (APL) characterized by t(15;17) translocation or PML/RAR-alpha gene expression (FDA approved in ages &ge;4 years and adults); has also been used in the initial treatment of APL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401582\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Multiple concentrations: Arsenic trioxide is available in different concentrations; verify concentration prior to admixture to assure appropriate dose preparation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136755\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial arrhythmia, chest pain, ECG abnormality (non-QT prolongation), edema, facial edema, flushing, hypertension, hypotension, palpitations, prolonged Q-T interval on ECG (&gt;500 msec), tachycardia, torsades de pointes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, coma, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, pain, paresthesia, rigors, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis, diaphoresis, erythema, hyperpigmentation, night sweats, pallor, pruritus, skin lesion, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, hyperglycemia, hyperkalemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, intermenstrual bleeding, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distension, abdominal pain, abdominal tenderness, anorexia, bloody diarrhea, constipation, decreased appetite, diarrhea, dyspepsia, fecal incontinence, gastrointestinal hemorrhage, loose stools, nausea, oral bullae, oral candidiasis, sore throat, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Oliguria, urinary incontinence, vaginal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, APL differentiation syndrome, bruise, disseminated intravascular coagulation, febrile neutropenia, hemorrhage, hyperleukocytosis, leukocytosis, lymphadenopathy, neutropenia, petechia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacterial infection, herpes simplex infection, herpes zoster, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, local skin exfoliation, pain at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, myalgia, neck pain, ostealgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, eye irritation, eye redness (with pain), eyelid edema, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Abnormal breath sounds (decreased), cough, dyspnea, epistaxis, hemoptysis, hypoxia, nasopharyngitis, pleural effusion, post nasal drip, rales, rhonchi, sinusitis, tachypnea, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Atrioventricular block, bone marrow necrosis, cardiac failure, deafness, heart block, increased gamma-glutamyl transferase, malignant melanoma, pancytopenia, paresis, peripheral neuropathy, rhabdomyolysis, squamous cell carcinoma, toxic epidermal necrolysis, ventricular premature contractions, ventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136721\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to arsenic or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136706\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Differentiation syndrome: <b>[US Boxed Warning]: </b><b>Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced symptoms of differentiation syndrome (may be fatal if not treated). Symptoms may include fever (unexplained), dyspnea, acute respiratory distress, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, weight gain or peripheral edema, hypotension, and renal, hepatic, or multiorgan dysfunction, occurring with or without leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until signs/symptoms resolve. May require temporary discontinuation of arsenic trioxide. </b>The onset of differentiation syndrome has occurred as early as day 1 of induction to as late as the second month of induction therapy. Prophylaxis with prednisone is recommended when arsenic trioxide is used in combination with tretinoin. At the first signs of differentiation syndrome, interrupt arsenic trioxide and administer dexamethasone 10 mg IV twice daily; continue high-dose corticosteroids until signs/symptoms have abated for at least 3 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: In newly diagnosed low-risk APL studies, patients treated with arsenic trioxide in combination with tretinoin experienced elevated AST, alkaline phosphatase, and/or serum bilirubin, which usually resolved with temporary discontinuation of arsenic trioxide and/or tretinoin. Monitor LFTs at least 2 to 3 times a week during arsenic trioxide treatment and continue monitoring until toxicity recovers. Withhold arsenic trioxide treatment and/or tretinoin if AST, alkaline phosphatase, and/or serum bilirubin elevations &gt;5 times the ULN occur. Long-term hepatic abnormalities may occur in patients with APL treated with arsenic trioxide in combination with tretinoin. Mild hepatic dysfunction and hepatic steatosis have been observed at a median of 7 years (range: up to 14 years) following arsenic trioxide and tretinoin combination therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: <b>[US Boxed Warning]: Arsenic trioxide may cause QTc interval prolongation, atrioventricular block, and a torsade des pointes-type ventricular arrhythmia, which may be fatal. </b><b>Prior to treatment initiation, assess the QTc interval (by ECG), correct preexisting electrolyte abnormalities, and consider discontinuing medications known to prolong QTc interval. Do not administer arsenic trioxide to patients with ventricular arrhythmia or prolonged QTcF. </b>In newly diagnosed low-risk APL studies, some patients who received arsenic trioxide in combination with tretinoin experienced QTc prolongation &gt;450 msec (for males) and &gt;460 msec (for females) throughout treatment cycles. In studies for relapsed or refractory APL, over one-third of patients who received arsenic trioxide (as monotherapy) had at least one ECG with a QTc interval &gt;500 msec. Prolonged QTc has been observed between 1 and 5 weeks after start of arsenic trioxide treatment, and usually resolved by 8 weeks after treatment. There are no data on the effect of arsenic trioxide on the QTc interval during the infusion. The risk of torsades de pointes is related to the extent of QTc prolongation, concurrent use of QTc prolonging medications, a history of torsade des pointes, preexisting QTc interval prolongation, heart failure, concurrent potassium-wasting diuretics, or other conditions associated with hypokalemia or hypomagnesemia. The risk may be increased when arsenic trioxide is coadministered with medications associated with electrolyte abnormalities (eg, diuretics or amphotericin B). If it is not possible to discontinue concomitant medications associated with QTc prolongation, perform cardiac monitoring frequently. Maintain serum potassium &gt;4 mEq/L and magnesium &gt;1.8 mg/dL during treatment. Monitor ECG weekly (more frequently in clinically unstable patients). If QTc &gt;500 msec develops, immediately withhold arsenic trioxide treatment and any medication known to prolong the QTc interval and correct electrolyte abnormalities; when the QTc normalizes, resume arsenic trioxide at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Arsenic trioxide is a human carcinogen; monitor for the development of second primary malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor closely for toxicity in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment (dose reduction may be warranted); systemic exposure may be higher; monitor closely for toxicities. Arsenic trioxide has not been studied in dialysis patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple concentrations: Arsenic trioxide is available in different concentrations; verify concentration prior to admixture to assure appropriate dose preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298770\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136710\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16769&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136723\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and findings in animal reproduction studies, arsenic may cause fetal harm if administered during pregnancy. Arsenic crosses the human placenta. In studies of women exposed to high levels of arsenic from drinking water, cord blood levels were similar to maternal serum levels. Dimethylarsinic acid (DMA) was the form of arsenic found in the fetus. An increased risk of low birth weight and still births were observed in women who ingested high levels of dietary arsenic. Verify pregnancy status in females of reproductive potential prior to initiating therapy. Females of reproductive potential should use effective contraception during treatment and for 6 months after the final arsenic trioxide dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final arsenic trioxide dose. An international consensus panel has published guidelines for the management of hematologic malignancies during pregnancy; arsenic trioxide is teratogenic and should not be used throughout pregnancy (Lishner 2016). Arsenic trioxide may impair fertility in males of reproductive potential (based on findings in animal studies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999104\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline then weekly 12-lead ECG; monitor electrolytes, CBC with differential, and coagulation at baseline then at least twice weekly during induction and at least weekly during consolidation; more frequent monitoring may be necessary in unstable patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136705\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Arsenic trioxide induces apoptosis in APL cells via morphological changes and DNA fragmentation; also damages or degrades the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR) alpha</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136720\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Arsenious acid (As<sup>III</sup>): 562 L; widely distributed throughout body tissues; dependent on body weight and increases as body weight increases; orally administered arsenic trioxide distributes into the CNS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Arsenic trioxide is immediately hydrolyzed to the active form, arsenious acid (As<sup>III</sup>) which is methylated (hepatically) to the less active pentavalent metabolites, monomethylarsonic acid (MMA<sup>v</sup>) and dimethylarsinic acid (DMA<sup>v</sup>) by methyltransferases; As<sup>III</sup> is also oxidized to the minor metabolite, arsenic acid (As<sup>v</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: As<sup>III</sup>: 10 to 14 hours; MMA<sup>v</sup>: ~32 hours; DMA<sup>v</sup>: ~72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: As<sup>III</sup>: At the end of infusion (2 hours); MMA<sup>v</sup> and DMA<sup>v</sup>; ~10 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (MMA<sup>v</sup>, DMA<sup>v</sup>, and ~15% of a dose as unchanged As<sup>III</sup>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323000\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Trisenox Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/6 mL (6 mL): $1,069.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539820\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asadin (MY, TW);</li>\n      <li>Phenasen (AU);</li>\n      <li>Trisenox (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IT, JP, KR, LT, LU, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Au WY, Tam S, Fong BM, et al, &quot;Determinants of Cerebrospinal Fluid Arsenic Concentration in Patients With Acute Promyelocytic Leukemia on Oral Arsenic Trioxide Therapy,&quot; <i>Blood</i>, 2008, 112(9):3587-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/18703707/pubmed\" target=\"_blank\" id=\"18703707\">18703707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Concha G, Vogler G, Lezcano D, et al, &quot;Exposure to Inorganic Arsenic Metabolites During Early Human Development,&quot; <i>Toxicol Sci</i>, 1998, 44(2):185-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/9742656/pubmed\" target=\"_blank\" id=\"9742656\">9742656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc,&quot; Food and Nutrition Board, Institute of Medicine. National Academy of Sciences, Washington, DC: National Academy Press, 2001, 162-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox E, Razzouk BI, Widemann BC, et al, &quot;Phase 1 Trial and Pharmacokinetic Study of Arsenic Trioxide in Children and Adolescents With Refractory or Relapsed Acute Leukemia, Including Acute Promyelocytic Leukemia or Lymphoma,&quot; <i>Blood</i>, 2008, 111(2):566-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/17959855/pubmed\" target=\"_blank\" id=\"17959855\">17959855</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gore SD, Gojo I, Sekeres MA, et al, &quot;Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia,&quot; <i>J Clin Oncol</i>, 2010, 28(6):1047-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/20085935/pubmed\" target=\"_blank\" id=\"20085935\">20085935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22715121\"></a>Iland HJ, Bradstock K, Supple SG, et al; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i>. 2012;120(8):1570-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/22715121/pubmed\" target=\"_blank\" id=\"22715121\">22715121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathews V, George B, Chendamarai E, et al, &quot;Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data,&quot; <i>J Clin Oncol</i>, 2010, 28(24):3866-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/20644086/pubmed\" target=\"_blank\" id=\"20644086\">20644086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathews V, George B, Lakshmi KM, et al, &quot;Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions With Minimal Toxicity,&quot; <i>Blood</i>, 2006, 107(7):2627-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/16352810/pubmed\" target=\"_blank\" id=\"16352810\">16352810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell BL, Moser B, Stock W, et al, &quot;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&quot; <i>Blood</i>, 2010, 116(19):3751-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/20705755/pubmed\" target=\"_blank\" id=\"20705755\">20705755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell BL, Moser B, Stock W, et al, &quot;Effect of Consolidation With Arsenic Trioxide (As2O3) on Event-Free Survival (EFS) and Overall Survival (OS) Among Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL): North American Intergroup Protocol C9710,&quot; <i>J Clin Oncol</i>, 2007, 25(18s):2 [abstract 2 from 2007 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ravandi F, Estey E, Jones D, et al, &quot;Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,&quot; <i>J Clin Oncol</i>, 2009, 27(4):504-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/19075265/pubmed\" target=\"_blank\" id=\"19075265\">19075265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, et al, &quot;Pregnancy Outcomes, Infant Mortality, and Arsenic in Drinking Water in West Bengal, India,&quot; <i>Am J Epidemiol</i>, 2006,163(7):662-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/16651647/pubmed\" target=\"_blank\" id=\"16651647\">16651647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang CY, Chang CC, Tsai SS, et al, &quot;Arsenic in Drinking Water and Adverse Pregnancy Outcome in an Arseniasis-Endemic Area in Northeastern Taiwan,&quot; <i>Environ Res</i>, 2003, 91(1):29-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-pediatric-drug-information/abstract-text/12550085/pubmed\" target=\"_blank\" id=\"12550085\">12550085</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16769 Version 105.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708626\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F136731\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22781459\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F999071\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F999096\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136716\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F136702\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F999102\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130882\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F136727\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F999072\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401582\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136755\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136721\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136706\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298770\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136710\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136723\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F999104\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136705\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F136720\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323000\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539820\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16769|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">Arsenic trioxide: Drug information</a></li><li><a href=\"topic.htm?path=arsenic-trioxide-patient-drug-information\" class=\"drug drug_patient\">Arsenic trioxide: Patient drug information</a></li></ul></div></div>","javascript":null}